BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26256907)

  • 1. Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma.
    Pellicelli AM; D'Ambrosio C; Dessanti ML; Villani R; Fondacaro L; Miglioresi L; Grillo LR; Andreoli A
    Ann Hepatol; 2015; 14(5):756-61. PubMed ID: 26256907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
    Visco C; Finotto S
    World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia.
    Mahale P; Turturro F; Romaguera JE; Fowler N; Torres HA
    Leuk Lymphoma; 2016; 57(6):1487-90. PubMed ID: 26402559
    [No Abstract]   [Full Text] [Related]  

  • 5. [Reactivation of hepatitis B virus in a patient treated for non-Hodgkin B diffuse large cell lymphoma with rituximab: about a case].
    Houssou B; Massi RM; Camara M; Mifdal H; Nourichafi N; Zafad S; Oukkache B
    Pan Afr Med J; 2015; 22():22. PubMed ID: 26664523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy.
    Lu S; Xu Y; Mu Q; Cao L; Chen J; Zhu Z; Lou Y; Meng H; Qian W; Tong H; Mai W; Huang J; Yu W; Zhao X; Jin J
    Leuk Lymphoma; 2015 Apr; 56(4):1027-32. PubMed ID: 25065698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
    Salah-Eldin MA; Ebrahim MA; El-Sadda W
    Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma.
    Hsieh CY; Huang HH; Lin CY; Chung LW; Liao YM; Bai LY; Chiu CF
    J Clin Oncol; 2008 May; 26(15):2584-6. PubMed ID: 18487576
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
    Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):379-84. PubMed ID: 21729690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
    Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
    Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
    Li X; Lin Q; Dong M; Wen JY; Wei L; Ma XK; Chen ZH; Wu XY
    Leuk Lymphoma; 2010 Sep; 51(9):1678-85. PubMed ID: 20807095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
    Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
    Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does rituximab really induce hepatitis C virus reactivation?
    Ennishi D; Yokoyama M; Terui Y; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
    J Clin Oncol; 2008 Oct; 26(28):4695-6; author reply 4696. PubMed ID: 18824720
    [No Abstract]   [Full Text] [Related]  

  • 17. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Tien YC; Yen HH; Chiu YM
    Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B.
    Wu CY; Hsiao LT; Chiou TJ; Gau JP; Liu JH; Yu YB; Wu YT; Liu CJ; Huang YC; Hung MH; Chen PM; Huang YH; Tzeng CH
    Leuk Lymphoma; 2015; 56(8):2357-64. PubMed ID: 25459444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral therapies for managing viral hepatitis in lymphoma patients.
    Merli M; Rattotti S; Gotti M; Arcaini L
    Expert Opin Pharmacother; 2017 Mar; 18(4):363-376. PubMed ID: 28140702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.